AR104539A1 - Compuestos cíclicos - Google Patents

Compuestos cíclicos

Info

Publication number
AR104539A1
AR104539A1 ARP160101293A ARP160101293A AR104539A1 AR 104539 A1 AR104539 A1 AR 104539A1 AR P160101293 A ARP160101293 A AR P160101293A AR P160101293 A ARP160101293 A AR P160101293A AR 104539 A1 AR104539 A1 AR 104539A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
ring
substituents selected
hydroxy
Prior art date
Application number
ARP160101293A
Other languages
English (en)
Inventor
Kitamoto Naomi
Tanaka Takahiro
Yamasaki Masashi
Katoh Taisuke
Negoro Nobuyuki
Nara Hiroshi
Wada Yasufumi
Saitoh Morihisa
Kobayashi Toshitake
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR104539A1 publication Critical patent/AR104539A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/12—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto representado por la fórmula (1) o una sal del mismo (caracterizado porque, el anillo A es ciclopenteno o ciclohexeno; el anillo B es un anillo de benceno sustituido en forma opcional por 1 a 3 sustituyentes seleccionados entre un átomo de halógeno y un grupo alquilo C₁₋₆; en cuanto a R¹ y R², (i) R¹ y R² son ambos átomos de hidrógeno, o (ii) uno de R¹ y R² es un átomo de hidrógeno, y el otro es un grupo hidroxi, o R¹ y R² se pueden unir entre sí para formar un heterociclo monocíclico no aromático de 3 a 8 miembros, que está sustituido en forma opcional por 1 a 3 grupos alquilo C₁₋₆ sustituidos en forma opcional por 1 a 3 sustituyentes seleccionados de un grupo hidroxi y un grupo alcoxi C₁₋₆; W es CH₂ u O; y R³ es un grupo alcoxi C₁₋₆ sustituido en forma opcional por 1 a 3 grupos cicloalquilo C₃₋₁₀ sustituidos en forma opcional por 1 a 3 grupos alquilo C₁₋₆).
ARP160101293A 2015-05-08 2016-05-06 Compuestos cíclicos AR104539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015095817 2015-05-08

Publications (1)

Publication Number Publication Date
AR104539A1 true AR104539A1 (es) 2017-07-26

Family

ID=56132991

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101293A AR104539A1 (es) 2015-05-08 2016-05-06 Compuestos cíclicos

Country Status (11)

Country Link
US (3) US9611244B2 (es)
EP (1) EP3294706B1 (es)
JP (1) JP6718884B2 (es)
CN (1) CN107835800B (es)
AR (1) AR104539A1 (es)
CA (1) CA2985325C (es)
EA (1) EA033083B1 (es)
ES (1) ES2772703T3 (es)
TW (1) TW201704206A (es)
UY (1) UY36675A (es)
WO (1) WO2016182036A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104539A1 (es) * 2015-05-08 2017-07-26 Takeda Pharmaceuticals Co Compuestos cíclicos
RU2742337C2 (ru) 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1063228E (pt) 1998-03-09 2005-05-31 Takeda Pharmaceutical Derivados de cicloalcenos processo para a sua preparacao e utilizacao
EP1209149B9 (en) 1999-08-06 2011-08-31 Takeda Pharmaceutical Company Limited Substituted aromatic-ring compounds, process for producing the same, and use
JP2004002370A (ja) * 2002-04-08 2004-01-08 Takeda Chem Ind Ltd 重症セプシス予防治療剤
WO2003084527A1 (fr) 2002-04-08 2003-10-16 Takeda Chemical Industries, Ltd. Agent therapeutique pour la prevention d'etat septique grave
CA2622694C (en) * 2005-09-14 2011-02-08 Daiichi Sankyo Company, Limited Substituted cycloalkene derivative
JP2008260760A (ja) * 2007-03-12 2008-10-30 Daiichi Sankyo Co Ltd 置換シクロアルケン誘導体を含有する医薬組成物
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
CN104744321A (zh) 2010-01-27 2015-07-01 武田药品工业株式会社 用于抑制由抗癌剂诱导的外周神经障碍的化合物
AR104539A1 (es) * 2015-05-08 2017-07-26 Takeda Pharmaceuticals Co Compuestos cíclicos

Also Published As

Publication number Publication date
US9611244B2 (en) 2017-04-04
BR112017023818A2 (pt) 2018-07-31
CA2985325A1 (en) 2016-11-17
CN107835800B (zh) 2019-11-26
ES2772703T3 (es) 2020-07-08
CN107835800A (zh) 2018-03-23
CA2985325C (en) 2023-09-26
EA201792469A1 (ru) 2018-06-29
JP2018516875A (ja) 2018-06-28
US9533966B2 (en) 2017-01-03
US20170066737A1 (en) 2017-03-09
US9828357B2 (en) 2017-11-28
EA033083B1 (ru) 2019-08-30
WO2016182036A1 (en) 2016-11-17
EP3294706A1 (en) 2018-03-21
TW201704206A (zh) 2017-02-01
US20160326102A1 (en) 2016-11-10
UY36675A (es) 2016-12-30
JP6718884B2 (ja) 2020-07-08
US20160326133A1 (en) 2016-11-10
EP3294706B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097866A1 (es) Derivados de 4-azaindol
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR098522A1 (es) Compuesto de triazolo-piridina
AR104539A1 (es) Compuestos cíclicos
AR104342A1 (es) Compuesto heterocíclico
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CU20170007A7 (es) Compuestos de imidazopiridazina
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
AR128158A2 (es) Compuesto heterocíclico
AR102957A1 (es) Combinaciones de compuestos activos
AR098965A1 (es) Derivados de sulfonamidas tricíclicas
CU24438B1 (es) Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido

Legal Events

Date Code Title Description
FB Suspension of granting procedure